Systemic sclerosis & Raynaud's
Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype
Authors' conclusion
Antivinculin antibodies associate with slower gastric transit in SSc and may provide insight into GI complications of SSc.
Study context
- Population
- Well-characterized patients with systemic sclerosis (SSc) and gastrointestinal (GI) disease
- Participants
- 88 patients
- Exposure
- SSc patients with vs without antivinculin antibodies
- Positive for antivinculin antibodiesn = 20
- Outcome
- Association of antivinculin antibodies with GI dysmotility (whole-gut scintigraphy) and extraintestinal clinical phenotype
Methodological detailsunivariate and multivariable analyses
- Univariate and multivariable analyses
Main finding
As reported in the abstract
Positive for antivinculin antibodies vs Without antibodiesOdds ratio (95% CI)
Limited cutaneous disease; univariate
9.60(1.19–77.23)
Thyroid disease; univariate
4.09(1.27–13.21)
- Antivinculin antibodies more prevalent in patients with slow gastric transit
- 35% versus 22%
- Higher antivinculin levels and gastric emptying, univariate
- β coefficient −3.41 (95% CI −6.72, −0.09)
- Higher antivinculin levels and gastric transit, multivariable
- β coefficient −3.64 (95% CI −7.05, −0.23)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype. Arthritis Care Res (Hoboken). Published 6 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →